Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%

MADRIGAL PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$19.31 revenue$76,813,000

Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.
Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.
Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.
Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.
Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.